Education Cannot Wait and Geneva Global Hub for Education in Emergencies Call for Sustained Support NEW YORK, Nov. 7, 2025…
New York City, NY, Nov. 01, 2025 (GLOBE NEWSWIRE) -- Introduction – Is Poor Sleep Ruining Your Days? If you’ve…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…
10 October 2025 - When Olympians speak openly about their mental health, they do more than share their stories – they…
Designed specifically for the U.S. at Kia’s design studio in California – and assembled in West Point, Georgia – the…
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on…
FLORENCE, Italy, July 2, 2025 /PRNewswire/ -- Medals and records alone are not enough to make history and actions, choices, and…
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…